Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases.

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to ...

Japan’s Eisai and US partner Biogen have announced today update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab (trade name Leqembi) as a treatment for early ...

As the nation kicks off Black History Month, a look into the industry shows there is a significant lack of Black leaders.

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. On this page, we're recording the regulatory progress of in-market products ... dose Spinraza is Biogen's answer to ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

Major stock indexes closed lower on Friday, after the week saw a flurry of events, including DeepSeek scare and earnings ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...